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mRNA exportAkt is a central player in the signal transduction pathways activated in response to many growth factors,
hormones, cytokines, and nutrients and is thought to control a myriad of cellular functions including prolif-
eration and survival, autophagy, metabolism, angiogenesis, motility, and exocytosis. Moreover, dysregulated
Akt activity is being implicated in the pathogenesis of a growing number of disorders, including cancer.
Evidence accumulated over the past 15 years has highlighted the presence of active Akt in the nucleus,
where it acts as a fundamental component of key signaling pathways. For example, nuclear Akt counteracts
apoptosis through a block of caspase-activated DNase: deoxyribonuclease and inhibition of chromatin con-
densation, and is also involved in cell cycle progression control, cell differentiation, mRNA: messenger RNA
export, DNA repair, and tumorigenesis. In this review, we shall summarize the most relevant ﬁndings
about nuclear Akt and its functions.
© 2012 Elsevier B.V. All rights reserved.1. Introduction
Akt is a 56-kDa member of the AGC serine/threonine protein kinase
family, discovered in 1991 [1,2]. In mammals, there are three genes,
located on different chromosomes, encoding for Akt1/α, Akt2/β, and
Akt3/γ. While Akt1 and Akt2 are ubiquitously expressed [3], Akt3 is
found predominantly in brain, kidney, and heart [4]. Akt isoforms
share a high degree of sequence homology in their catalytic domains,
but diverge in other regions of the protein, i.e. the C-terminus regulato-
ry domain and the N-terminus pleckstrin homology (PH) domain [3]
(Fig. 1). The kinase catalytic domain, located in the central region of
the protein, displays a high degree of similarity to those found in protein
kinase A (PKA) and protein kinase C (PKC), hence the other name of Akt,
protein kinase B (PKB) [5].
All three Akt isoforms undergo membrane recruitment through the
N-terminus PH domain which binds to phosphatidylinositol 3,4,5-
trisphosphate (PIP3) synthesized by phosphatidylinositol 3-kinase
(PI3K), leading to phosphorylation and activation of Akt kinase activity
[6]. The three isoforms contain similar phosphorylation sites: Thr 308
(Akt1)/Thr 309 (Akt2)/Thr 305 (Akt3) and Ser 473 (Akt1)/Ser 474cal and Neuromotor Sciences,
051 2091580; fax: +39 051
elli).
l rights reserved.(Akt2)/Ser 472 (Akt3) [3] (Fig. 1). The Thr residues are phosphorylated
by phosphoinositide-dependent protein kinase 1 (PDK1), which is also
recruited to the plasma membrane by PIP3 [7,8]. In contrast, the Ser
residues are targeted by mammalian target of rapamycin complex 2
(mTORC2) [9]. However, the Ser residues can be phosphorylated by
other kinases, including integrin-linked kinase (ILK) [10]. Together,
the two phosphorylation events cause full activation of Akt, however,
in the absence of Ser 473 phosphorylation, Thr 308 p-Akt can still
phosphorylate some, but not all, of its substrates [11].
Akt is inactivated through the action of protein phosphatases.
The Thr residues are dephosphorylated by protein phosphatase 2A
(PP2A) [12]. The core enzyme of PP2A is a dimer consisting of a
catalytic subunit (PP2A/Cα or β) and a regulatory/structural A
subunit (PP2A/Aα or β). A third regulatory B subunit (PP2A/B), that
determines substrate speciﬁcity, can be associated with this core
structure [13].
The Ser residues are targeted by the pleckstrin homology domain
leucine-rich repeat protein phosphatase (PHLPP) family of isozymes.
Three PHLPP isoforms have been identiﬁed so far, the alternatively
spliced PHLPP1α and PHLPP1β, and PHLPP2 [14]. These PHLPP
isoforms are involved in the dephosphorylation of speciﬁc Akt iso-
zymes. PHLPP1 targets Akt2 and Akt3, while PHLPP2 dephosphory-
lates Akt1 and Akt3 [15].
Akt was ﬁrst characterized for its function in regulating cell prolif-
eration and survival. This could be due to the direct or indirect effects
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Akt leads to cell cycle dysregulation and inhibition of pro-apoptotic
pathways that are typical hallmarks of human tumors [16]. Therefore,
over-activation of Akt signaling is oncogenetic [17]. Consistently, Akt
activity is up-regulated in many types of neoplasia where it is
involved in drug-resistance [18]. For this reason, Akt is regarded as
a potential therapeutic target for innovative treatments of cancer,
and some Akt inhibitors are now being tested in clinical trials in
cancer patients [19,20].
Once activated, Akt isoforms translocate to various subcellular
compartments, including the endoplasmic reticulum, the mitochon-
dria, the Golgi, and the nucleus, where they phosphorylate substrates
or interact with other cell components.
Here, we shall highlight the existing evidence on the multiple
roles played by Akt in the nucleus. However, for a better understand-
ing of this review, it is useful to brieﬂy recapitulate some general data
regarding both Akt and nuclear structure.
2. Functions and substrates of Akt
Akt constitutes an important node inmany signaling cascades down-
streamof growth factor receptor tyrosine kinases andG protein-coupled
receptors. As such, Akt isoforms play key roles in cell survival [17], pro-
liferation [21], growth [22], migration [23], polarity [24], insulin-evoked
glucose transport [25], glucose and lipid metabolism [26,27], contractil-
ity in both skeletal muscle [28] and cardiomyocytes [29], angiogenesis
[30], and self-renewal of stem cells [31–33]. Impaired Akt activity has
been associated not only with cancer [34–36], but also with other disor-
ders, that include type 2 diabetes, cardiovascular and neurodegenerative
diseases, and muscle hypotrophy [37,38].
Akt substrates often contain the phospho-Akt-substrate consensus
motif (R-X-R-X-X-S/T) [39]. Consensus motif analysis indicates that
there are potentially thousands of cellular substrates for Akt, however
only about 60–70 of these have been characterized so far. Akt may
either positively or negatively affect the functions of these substrates
(although many of them are usually inhibited), alter their subcellular
localization, or modify their stability.
Promoters of apoptosis that are inhibited by Akt include the FOXO
family members of transcription factors, FOXO1a, FOXO3a, and
FOXO4 [40,41]. Phosphorylation of FOXO family members by Akt
leads to their nuclear exclusion and inactivation, with a consequent
decreased transcription of mRNAs coding for proteins (BH3-onlyChromosome
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Fig. 1. Domain structure of Akt isoforms. All the Akt isoforms possess a catalytic
(kinase) domain in the central region of the molecule. The PH domain acts as a phos-
phatidylinositol 3,4,5-trisphosphate-binding module. The RD is located at the C-
terminus, adjacent to the kinase domain. Phosphorylation sites in the activation loop
of the catalytic domain and in the RD are indicated. The percentage of sequence homol-
ogy of the three isoforms as well as the chromosome location of the genes coding for
the Akt isozymes are also highlighted. Abbreviations: PH, pleckstrin homology; RD,
regulatory domain.family proteins and Fas-ligand, for example) that are required for
promoting apoptosis [42,43]. However, Akt delivers anti-apoptotic
signals through proteins whose function is directly modulated by
Akt phosphorylation. Bad was one of the ﬁrst discovered targets of
Akt [44]. Bad is a pro-apoptotic member of the Bcl-2 family of pro-
teins, which binds Bcl-2 or Bcl-XL, thus blocking their anti-apoptotic
activities. Phosphorylation of Bad on Ser 136 by Akt disrupts Bad
interactions with Bcl-2/Bcl-XL, localized on the outer mitochondrial
membrane. As a consequence, Bad is sequestered in the cytosol,
through the interaction with 14-3-3 protein [45]. In an analogous
way, phosphorylation by Akt of pro-apoptotic Bax on Ser 184 blocks
Bax translocation to mitochondria, thus preventing Bax conforma-
tional change, an event that occurs after apoptotic induction [46].
Akt phosphorylates apoptosis signaling kinase 1 (ASK-1) at Ser 83,
which attenuates ASK-1 activity and promotes cell survival, as ASK-1
transduces stress signals to the pro-apoptotic jun NH2-terminal kinase
or JNK and p38 MAP kinase cascades [47].
Targets activated by Akt for promoting cell survival, include the
inhibitor of kappa B kinase-α (IKKα), which in turn phosphorylates
and thereby promotes the degradation of the inhibitory cofactor of
NF-κB, I-κB [48]. This allows NF-κB to translocate to the nucleus
where it stimulates the transcription of pro-survival genes, such as
those coding for inhibitor of apoptosis protein (IAP) 1 and IAP2 [49].
Akt positively regulates cyclic AMP-response element binding
protein (CREB) activity, however in this case by direct phosphoryla-
tion [50,51]. CREB phosphorylation at Ser 133 by Akt then induces
the binding of accessory proteins that are necessary for the transcription
of anti-apoptotic genes, including Bcl-2 and Mcl-1 [49,52]. Murine dou-
ble minute 2 (MDM2) is an E3 ubiquitin ligase whose expression is in-
duced by the p53 tumor suppressor. As a feed-back loop, MDM2
negatively controls intracellular levels of p53, a major cell death effector
[53]. Phosphorylation of MDM2 at Ser 166 and Ser 186 by Akt decreases
MDM2 self-ubiquitination and renders the protein more stable. As a
consequence, p53-mediated apoptosis is inhibited [54].
As to cell proliferation, Akt phosphorylates p21Waf1/Cip1 and
p27Kip1, two members of the Cip/Kip family of cyclin-dependent
kinase (CDK) inhibitors. Both p21Waf1/Cip1 and p27Kip1 associate
with CDK/cyclin complexes, and serve to inhibit kinase activity and
block progression through the G1/S transition of the cell cycle [55].
Akt phosphorylates p21Waf1/Cip1 at both Thr 145 and Ser 146. Thr
145 phosphorylation results in the cytoplasmic localization of
p21Waf1/Cip1 and thus promotes the cell cycle [56], whereas the Ser
146 site phosphorylation enhances the stability of the protein and
further increases the assembly of cyclin D-CDK4 G1/S transition
complex [43]. Akt-mediated phosphorylation of p27Kip at Thr 157
causes the relocation of p27Kip to the cytoplasm, thus relieving the
nuclear substrates (CDK2/cyclin E and CDK2/cyclin A) from p27Kip
inhibition and enhancing cell cycle progression [57].
Moreover, Akt phosphorylates and inactivates glycogen synthase
kinase (GSK) 3β. GSK3β phosphorylates cyclin D1 at Thr 286 [58]
and Myc at Thr 58 [59], which promotes their nuclear export and
degradation via the ubiquitin-mediated pathway. Thus, inhibition of
GSK3β activity by Akt-mediated phosphorylation facilitates the G1/S
progression of the cell cycle.
Akt plays a key role in promoting cell growth. The predominant
mechanism appears to be through the activation of the mammalian
target of rapamycin complex 1 (mTORC1), which is regulated by
both nutrients and growth factor signaling [60]. Akt phosphorylates
200-kDa tuberous sclerosis 2 (TSC2 or hamartin). TSC2 is a GTPase
activating protein (or GAP) protein which associates with 130-kDa
tuberous sclerosis 1 (TSC1 or tuberin) to inactivate the small G pro-
tein Ras homolog enriched in brain (Rheb). Once phosphorylated by
Akt at Thr 1462 [61], TSC2 binds 14-3-3 proteins [62]. Upon binding
to 14-3-3 proteins, TSC2 is degraded by the proteasome, and Rheb
accumulates in a GTP-bound state, which activates mTORC1 [63].
Moreover, another Akt substrate is involved in mTORC1 control, the
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tive regulator of mTORC1 activity [64]. Akt directly phosphorylates
PRAS40 on Thr 246 [65], and this phosphorylation is fundamental
for 14-3-3 protein binding to PRAS40 which relieves mTORC1 from
PRAS40 inhibition [66].
Nevertheless, it should be emphasized that Akt regulation of
mTORC1 is important for cell proliferation and survival, as mTORC1
controls the translation of numerous proteins involved in cell cycle
progression and anti-apoptotic signaling [67].
3. Nuclear structure
The nucleus is the organelle where processes such as DNA replica-
tion, transcription, and mRNA processing take place. Major advances
in cytological methods and molecular genomics have provided funda-
mental insights on nuclear organization. The nucleus is separated
from the cytoplasm by the nuclear envelope (NE) that compartmen-
talizes the genetic material from the protein translation machinery
in the cytoplasm. The NE is a highly organized membranous structure
comprising the outer and inner nuclear membranes, nuclear pore
complexes (NPCs), and the nuclear lamina [68]. The outer nuclear
membrane is directly continuous with the rough endoplasmic reticu-
lum containing ribosomes while the inner nuclear membrane con-
tains unique sets of intrinsic and extrinsic proteins that bind the
nuclear lamina and chromatin [69]. NPCs serve as aqueous channels
for nuclear import/export of high molecular weight molecules [70].
The nuclear lamina is an intermediate ﬁlament protein meshwork
anchored to the inner nuclear membrane which provides structural
support to the nucleus and interacts directly with chromatin
[71,72]. As to the nuclear interior, several lines of evidence suggest
that it displays a compartmentalized structure, consisting of chromo-
some territories (CTs) and an interchromatin compartment (IC). CTs
comprise a hierarchy of chromatin domains starting with DNA loop
domains with an average DNA content ranging from about 30 to
200 kilobases (kb), referred to as 100 kb chromatin domains. This
model of nuclear organization predicts that a series of loop domains
forms larger chromatin domains with DNA contents of several hun-
dred kb to several megabases (Mb), referred to as 1 Mb chromatin
domains [73]. Large chromosomes are found more often at the nucle-
ar periphery, while small chromosomes are found more interiorly.
However, the spatial separation of chromosomes in the nucleus is
not absolute, as chromosomal intermingling occurs at the periphery
of the territories. A further division can be found within the CTs,
with gene-poor and gene-rich regions spatially separated [74].
Gene-poor CTs and silenced genes are frequently found in association
with the nuclear periphery, a similar location to that of heterochro-
matin. In contrast, gene-rich CTs and active genes localize to the nu-
clear interior [75]. The IC has been envisaged as a three-dimensional
network of lacunas and channels, which starts at the nuclear pores
and then expands both between neighboring CTs and into the interior
of individual CTs. The IC is lined by the surface of smaller and larger
chromatin domains [76]. It has been suggested that the IC and the
border zone between chromatin domains and the IC, referred to as
the perichromatin region, possess a deﬁned topology that is essential
for transcription, RNA splicing, DNA replication, and presumably also
for DNA repair [77].
It should be considered that the nucleus is unique amongst
cellular organelles as it contains a myriad of discrete suborganelles,
referred to as nuclear bodies [78]. Nuclear bodies are morphologically
and molecularly distinct dynamic entities that further compartmen-
talize the IC. Therefore, they create microenvironments within the
nucleus where speciﬁc nuclear processes take place. At variance
with cytoplasmic organelles, nuclear bodies are not surrounded by
lipid membranes, and their structural integrity is completely mediat-
ed by protein–protein and, possibly, by protein–RNA interactions
[78].4. Nuclear Akt
The presence of active, phosphorylated Akt (p-Akt) within the
nucleus has been reported since the late 1990s. Indeed, some of Akt
substrates are resident in the nucleus, such as the FOXO family of
transcription factors [79] or the transcriptional coactivator p300
[80]. Akt1, Akt2, and Akt3 have been reported to reside in the nucleus
or to migrate into the nucleus in response to a wide variety of stimuli
that include insulin-like growth factor-1 (IGF-1), F(ab′)2 fragment of
anti‐mouse IgG acting on B-cell receptor, hypoglycemia, insulin, and
nerve growth factor (NGF) [81–86].
The nuclear localization sequence (NLS) motif of Akt is unknown,
however the proto-oncogene T-cell leukemia-1 (TCL1) protein family
may be involved in Akt nuclear localization, as ﬁrst demonstrated in
human T-cell leukemia [87]. Three TCL1 isoforms have been identiﬁed
in both the human and the mouse genome: TCL1, TCL1B, and MTCP1
(mature T cell proliferation 1) [88]. TCL1 binds to the PH domain of
Akt and mediates the formation, at the plasma membrane level,
of TCL1-Akt high-molecular-weight protein complexes. Akt is then
preferentially phosphorylated and activated within these complexes
[89]. In two-cell mouse embryos that were genetically deﬁcient in
TCL1, phosphorylated Akt had a striking cortical localization and
was lacking in blastomere nuclei [90]. Moreover, when the levels of
TCL1B were reduced by siRNA in T47-D breast cancer cells, a decrease
in the levels of nuclear (but not cytoplasmic) p-Akt was observed.
Conversely, when TCL1B was overexpressed in either MCF-7 or
T47-D cells, an increase in the amount of nuclear p-Akt was detected
[91]. These ﬁndings highlighted the important role played by TCL1 in
nuclear targeting of Akt. However, further studies are necessary to
establish whether the TCL1–Akt interactions are a universal mecha-
nism required for nuclear import of Akt. Indeed, while TCL1 proteins
are usually expressed at high levels in embryonic/fetal cells and in
various stages of B- and T-cell development, their levels in healthy
adult tissues are low, at least in mouse [88]. Nevertheless, the expres-
sion of TCL1 proteins is up-regulated in some solid and hematologic
cancer types [91,92]. This ﬁnding could somehow explain the in-
creased nuclear localization of Akt which is observed in some kinds
of cancer.
Whether or not Akt needs to be phosphorylated for entering the
nucleus is controversial. Indeed, it has been documented that
unphosphorylated Akt could migrate to the nucleus in HEK293 cells
overexpressing kinase-dead Akt mutants (T308A, S473A) that could
not be phosphorylated, suggesting that phosphorylation of Akt was
not required for its nuclear localization [93]. In contrast, overexpression
of the same mutants impaired Akt nuclear translocation after NGF
stimulation of PC12 cell [94]. It was therefore concluded that activity
and phosphorylation of Akt kinase were involved, at least to some
degree, in Akt nuclear translocation [94]. It is conceivable that these
discrepancies are dependent on the different cell types/stimuli used.
Another controversial issue regards whether or not Akt can be phos-
phorylated within the nucleus. The nucleus contains all the machinery
necessary for phosphorylating Akt at Thr 308, including PI3K [95],
PIP3 [96], and PDK1 [97,98]. Moreover, mTORC2 has been demonstrat-
ed to localize to the nucleus in aggressive variants of papillary thyroid
carcinomas, concomitantly with high levels of Ser 473 p-Akt. Therefore,
it has been hypothesized that mTORC2 could phosphorylate Akt at Ser
473 within the nucleus of thyroid neoplastic cells [99]. In this connec-
tion, it is interesting that mTORC2 has been localized to both the
cytoplasm and the nucleus, whereas mTORC1 is predominantly cyto-
plasmic [100], even if anmTORC1 component, Raptor, has been recently
identiﬁed as a phosphoprotein involved in rDNA transcription in nucle-
oli [101,102].
Nevertheless, several lines of evidence indicate that Akt migrates
to the nucleus after having been phosphorylated at the plasma mem-
brane [103,104] and that nuclear PDK1 is not involved in phosphory-
lating Akt at Thr 308. Rather, it seems that PDK1 nuclear translocation
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signaling pathways [105]. However, other investigators have come
to opposite conclusions [106].
All three Akt isoforms possess a classic, leucine rich, leptomycin-
sensitive nuclear export sequence (NES). Accordingly, stable over-
expression of Akt1 displaying a non-functional NES, resulted in
persistent nuclear localization of Akt1 and enhanced cell migration
in vitro of Akt1−/− ﬁbroblasts [93].
5. Functions of nuclear Akt
5.1. Cell cycle progression
Considering the paramount role played by Akt in cell cycle
regulation, it is not surprising that Akt translocated to the nucleus
during early G1 phase of the cell cycle [107]. Moreover, MCF7 breast
cancer cells overexpressing a ΔNES-mutant (L277A/L280A/L282A)
Akt1, contained higher levels of nuclear p-Akt compared with cells
overexpressing the empty vector only. Higher levels of nuclear Akt
correlated with increased cyclin D1 expression and cell proliferation
in response to estradiol challenging [91]. Increased expression of
cyclin D1 by nuclear Akt may be related to the fact that Akt up-
regulates the histone acetyltransferase activity and transcriptional
activity of p300 [80] which is involved in the histone acetylation at
the cyclin D1 promoter and cyclin D1 gene transcription [108].
When a rapid depletion of nuclear p-Akt was induced by extracel-
lular ATP or statins in insulin-stimulated A549 cells, PHLPP1 and
PHLPP2 were recruited to the nucleus. PHLPP1 and PHLPP2 were
instrumental for Akt dephosphorylation, which, however, required
nuclear translocation of the PIP3 phosphatase, phosphatase and
tensin homolog deleted on chromosome 10 (PTEN) [109]. PTEN is a
tumor suppressor, as it down-regulates oncogenic PI3K/Akt signaling
by dephosphorylating PIP3 [110]. Upon nuclear Akt dephosphoryla-
tion and depletion, proliferating cell nuclear antigen (PCNA) and
p21Waf1/Cip1 translocated to the nucleus where they formed a com-
plex. It is known that nuclear PCNA/p21Waf1/Cip1 complexes cause
cell cycle arrest [111,112]. p110β PI3K was essential for nuclear
export of p-Akt in insulin-stimulated cells exposed to either statins
or elevated levels of extracellular ATP [113]. These ﬁndings are
consistent with a report which has documented an association
between p110β PI3K and Akt at the nuclear level [114]. Nuclear
p110β PI3K is involved in DNA replication, as its catalytic activity
was required for regulating the nuclear activation of Akt during the
S phase of the cell cycle and in turn the phosphorylation of the cell
cycle progression inhibitor, p21Waf1/Cip1 [114].
Overall, these ﬁndings have highlighted some signaling events
through which nuclear Akt could control cell cycle progression.
5.2. Cell survival
Akt signaling blocks cell death both by impinging on the cytoplas-
mic apoptotic machinery and by mediating the expression of genes
involved in cell death and survival. However, there is strong evidence
documenting a more direct role for nuclear Akt in apoptosis suppres-
sion. This function of Akt has been mainly investigated in PC12 neural
cells challenged with NGF and primary cardiomyocytes.
5.2.1. PC12 cells
NGF is the prototypical member of a family of neurotrophic factors
called neurotrophins that play key roles in cell survival, differentia-
tion, and growth arrest [115,116]. NGF stimulated phosphorylated
Akt to translocate to the nucleus of PC12 cells [86]. In a series of
seminal papers, Ye and coworkers have investigated the molecular
mechanisms underlying the anti-apoptotic effects of nuclear Akt in
PC12 cells challenged with NGF. They overexpressed wild-type,
constitutively active or dominant-negative Akt in PC12 cells, andtreated the cells with NGF. Upon NGF treatment, the nuclei isolated
from control cells, or from cells overexpressing either wild-type or
constitutively active Akt, were resistant in vitro to internucleosomal
cleavage caused by a pro-apoptotic apoptotic solution, consisting of
HEK293 cell cytosol supplemented with puriﬁed active caspase-3
[117]. In contrast, they observed DNA fragmentation in dominant-
negative Akt samples in spite of NGF treatment, indicating that nucle-
ar Akt was required for NGF-mediated anti-apoptotic signaling.
Nevertheless, without NGF treatment, all the nuclei displayed DNA
fragmentation even if they had been isolated from cells overex-
pressing constitutively active Akt. This indicated that Akt activation
alone was not sufﬁcient to inhibit DNA cleavage [118]. In an attempt
to search for nuclear Akt substrates contributing to blocking apopto-
sis, the same group identiﬁed acinus, a nuclear factor required for
apoptotic chromatin condensation after cleavage by caspase-3 [119].
Acinus is cleaved by caspase-3 on both its N- and C-termini,
producing a p17 active form, which triggers chromatin condensation
even in the absence of caspase-3. Full-length acinus is unable to induce
chromatin condensation, suggesting that caspase-mediated cleavage is
necessary for this activity [120]. Acinus, which resides in nuclear
speckles (a type of nuclear bodies), is a direct target of Akt [121]. Akt
phosphorylation of acinus on both Ser 422 and Ser 573 resulted in
acinus resistance to caspase cleavage in the nucleus and inhibition of
acinus-dependent chromatin condensation. If acinus phosphorylation
by Akt was abolished through mutagenesis, its proteolytic degradation
and chromatin condensationwere accelerated.Moreover, overexpression
of an acinus mutant that mimicked phosphorylation by Akt and was
resistant to apoptotic cleavage, prevented chromatin condensation [121].
Intriguingly, upon NGF stimulation of PC12 cells, nuclear Akt
phosphorylated zyxin, an 82-kDa focal adhesion protein that shuttles
between the nucleus and the cytoplasm and that antagonizes apopto-
sis [122]. Upon phosphorylation at Ser 142 by Akt, nuclear zyxin
robustly interacted with acinus and suppressed its apoptotic cleav-
age, resulting in inhibition of apoptotic chromatin condensation
[123]. Therefore, nuclear Akt provides a dual protection on acinus
by inducing a direct binding between zyxin and acinus and blocking
its proteolytic degradation, in addition to direct phosphorylation of
acinus.
In some cases, nuclear Akt is involved in NGF-dependent cell
survival through interactions with other proteins, that, however, are
not Akt substrates. One such protein is represented by ErbB-3 binding
protein (Ebp1), a ubiquitously expressed protein, which localizes in
both the nucleus and the cytoplasm and binds ErbB3 receptor in
human serum-starved breast cancer cell lines [124]. There are two
Ebp1 isoforms, p48 and p42. The longer-form p48 localizes in both
the cytoplasm and the nucleus, whereas the shorter-form p42
predominantly resides in the cytoplasm [125]. The p48 Ebp1 isoform
was identiﬁed in nuclear extracts prepared from NGF-challenged
PC12 cells as a protein which contributed to inhibition of DNA
fragmentation by caspase-activated DNase (CAD), also referred to as
DNA fragmentation factor or DFF. Nuclear (but not cytoplasmic)
p-Akt associated with PKC-phosphorylated Ebp1 and enhanced its
anti-apoptotic action. However, the kinase activity of Akt was not
required for Ebp1 binding. Ebp1 interacted with the N-terminus PH
and catalytic domains of Akt [126]. PKC-δ has been subsequently
identiﬁed as the PKC isoform that phosphorylates Ebp1 at Ser 360,
an event which prevented caspase-3-mediated proteolytic cleavage
and that was necessary for Ebp1/Akt interactions [127].
Another nuclear Akt-interacting protein is B23, also referred to as
nucleophosmin. B23 mainly localizes to the nucleolus and is thought
to play key roles in diverse cellular functions that include ribosome
biogenesis, cell cycle progression, DNA repair, centrosome duplica-
tion, and response to stress [128]. Furthermore, it is involved in the
pathogenesis of several human cancers, including acute myelogenous
leukemia (AML) [129]. Intriguingly, it has been described both as an
activating oncogene and a tumor suppressor, depending on cell type
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PH domain of Akt. Akt binding to B23 in response to NGF stimulation
of PC12 cells, protected B23 from proteolytic degradation by
caspase-3 in vitro and in vivo, leading to the up-regulation of cell
survival. Nuclear Akt phosphorylation, but not its kinase activity,
was required for Akt association with B23, in analogy with Akt inter-
actions with Ebp1 [130]. Moreover, a nuclear B23/Akt/PIP3 complex
inhibited DNA fragmentation effected by CAD/DFF, which is the
major apoptotic nuclease [131,132]. Overall, the above-highlighted
ﬁndings presented convincing evidence that nuclear Akt inhibits
apoptosis not only through phosphorylation of transcription factors
(e.g. FOXO proteins) but also through the direct targeting of apoptotic
effectors operating in the nucleus. Anti-apoptotic signaling controlled
by Akt in PC12 cells treated with NGF is highlighted in Fig. 2.
5.2.2. Cardiomyocytes
The anti-apoptotic role of nuclear Akt has been studied in some
detail in cardiomyocytes. Apoptosis occurs in a wide variety of cardio-
vascular disorders and is now recognized as a fundamental process
that contributes to deterioration of cardiac function characterizing
heart failure [133]. The key pathophysiological process that ultimate-
ly leads to chronic heart failure is cardiac remodeling (mainly due to
cardiomyocyte hypertrophy) in response to chronic disease stresses,
such as, for example, pressure overload due to hypertension [134]. It is
well established that short-term Akt activation promotes physiological
heart hypertrophy and protection from myocardial injury, whereas,
long-term Akt up-regulation causes pathological hypertrophy and
heart failure [29]. Interestingly, it seems that if p-Akt resides in the
nucleus, the negative effects of its up-regulated activity may be avoided
[135]. Aktwas selectively targeted to the nucleus of neonatal rat ventric-
ular cardiomyocytes by using an adenovirus shuttle vector in which
full-length wild-type mouse Akt cDNA was cloned upstream of three
in-frame NLS sequences. Akt targeting to the nucleus of cardiomyocytes
did not result in evidence of morphological remodeling, such as altered
myoﬁbril density or hypertrophy. Nuclear extracts from transfected
cardiomyocytes displayed elevated levels of both Thr 308 and Ser 473
p-Akt, as well an increase in Akt kinase activity. In contrast, the levels
of cytoplasmic Ser 473 p-Aktwere similar to control animals. Moreover,
nuclear targeted Akt was as effective as myristoylated-Akt in blocking
staurosporine-, deoxyglucose-, and hypoxia-induced apoptosis of
cardiomyocytes [136]. Also, cardiomyocytes from transgenic mice
were protected against ischemia–reperfusion injury and did not display
increased levels of phosphorylated Bad and GSK-3β, two cytoplasmic
Akt substrates. Of note, GSK-3β is involved in cardiomyocyte hypertro-
phy [137].
Taken together, these ﬁndings suggested that nuclear targeting of
Akt prevented apoptosis without inducing hypertrophic remodeling,
thus opening new possibilities for therapeutic applications to inhibit
cell death associated with heart disorders. Accordingly, Ser 473 p-Akt
levels increased in the nucleus of mouse cardiomyocytes after infarction
challenge. Therefore, Akt translocation to the nucleus couldbe interpreted
as a physiological mechanism aiming to protect cells from death due to
oxygen deprivation [106].
A subsequent study from the same group documented that nucle-
ar overexpression of Akt in mice did not modify left ventricular free
wall thickness, chamber diameter, longitudinal axis, and volume,
but rather resulted in an increased number of cardiomyocytes, that,
however, were smaller in volume [138]. Moreover, the heart from
transgenic animals was characterized by enhanced performance
involving both systolic and diastolic function, that were paralleled
by increased performance in the contraction of isolated ventricular
cardiomyocytes. Indeed, cardiomyocytes' shortening and velocity of
shortening/relengthening were increased and coupled with a more
efﬁcient reuptake of Ca2+ by the sarcoplasmic reticulum (SR). The
enhanced SR function was dependent upon an increase in SR
Ca2+-ATPase2a activity sustained by higher levels of phospholamban(PLN) phosphorylation. PLN regulates the function of sarcoplasmic
reticulum Ca2+-ATPase 2a (SERCA2a, the predominant contributor
of the Ca2+ inﬂux into the SR), and the unphosphorylated form of
PLN inhibits SERCA2a and thereby the reuptake of Ca2+ by the SR.
In contrast, the phosphorylated form of PLN enhances the activity
of SERCA2a and the transport of Ca2+ into the SR [139]. PLN
hyperphosphorylation was associated with an increase in p-PKAα
and a decrease in protein phosphatase-1 (PP1) levels. Taken together,
these observations provided a likely biochemical mechanism for the
potentiation of cardiomyocyte and ventricular function in nuclear
Akt transgenic mice, however it remains to be established how
increased expression of Akt in the nucleus could impact on p-PKAα
and PP1 levels [138].
It is very interesting that young women displayed higher levels of
nuclear-localized Ser 473 p-Akt relative to comparably aged men or
postmenopausal women. Considering that cardiovascular disease
risk is higher in men or postmenopausal women than in young
women, it is tempting to speculate that the activation of Akt in the
nucleus in a gender- and age-dependent manner may help to some-
how explain the differences observed in cardiovascular disease risk
[140]. Both the localization of Ser 473 p-Akt in cardiomyocyte nuclei
of sexually mature female mice versus males and Akt kinase activity
in nuclear extracts of hearts from female mice versus males were
elevated [140]. The differences could be dependent on estrogen, as
Ser 473 p-Akt was also localized to the nucleus of cultured mice
cardiomyocytes after exposure to 17β-estradiol or genistein (a phyto-
estrogen present in soy protein-based diets), and neonatal exposure
of mouse litters to genistein increased nuclear localization of Ser
473 p-Akt [140]. Therefore, increased levels of active Akt in the nucle-
us could somehow explain the protective effects of estrogens against
heart disorders [141].
Atrial natriuretic peptide (ANP) is a physiological regulator of ﬂuid
retention and blood pressure which could be of clinical beneﬁt in
some cardiovascular disorders such as hypertension, myocardial infarc-
tion, coronary heart disease, and cardiac failure [142]. Overexpression
of Akt in the nucleus induced ANP gene expression in vitro in murine
cardiomyocytes in a pressure overload model [135]. Moreover, exoge-
nous ANP promoted nuclear accumulation of Ser 473 p-Akt and
protected cardiomyocytes from staurosporine-mediated apoptosis.
Intriguingly, nuclear targeting of Akt in cardiomyocytes was accompa-
nied by migration to the nucleus of zyxin. Other cardioprotective
agents (IGF-1, adrenomedullin, and estrogens) promoted translocation
of zyxin to the nucleus [143]. This observation is consistent with the
results reported for PC12 cells challenged with NGF [123]. Therefore,
both Akt and zyxin could be part of a nuclear signaling network activat-
ed by different anti-apoptotic effectors.
5.3. DNA repair
Akt is activated in response to DNA damaging agents such as ionizing
radiation (IR) [144]. Activated Akt enhances the DNA damage-induced
transcription and promotes cell survival [145]. IR produces DNA double
strand breaks (DSB) [146]. Interestingly, DNA-dependent protein kinase
(DNA-PK),which is involved in DSB repair [147], has been identiﬁed as a
putative Ser 473 Akt kinase [148]. Another central player in DSB repair is
the ataxia-telangiectasia-mutated (ATM) kinase [149]. It has been
shown that a subset of Ser 473 p-Akt accumulated in the nucleus at
IR-induced foci where it co-localized with the DBS markers, γ-H2AX
and Ser 1981 p-ATM [150]. Ser p-473 Akt induction was independent
of both PI3K and DNA-PK, but was downstream of meiotic recombina-
tion 11 (MRE11)-dependent ATM activation and ring ﬁnger protein
168 (RNF168)-dependent histone ubiquitinylation. MRE11, togeth-
er with RAD50 and Nijmegen breakage syndrome 1 (or NBS1, also
known as nibrin), form the MRE11 complex, a sensor of DSB that
controls the DNA damage response by governing the activation of ATM
[151]. RNF168 is an E3 ubiquitin ligase which is involved in histone
Akt
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ﬂanking chromatin, an essential step for restoration of genome integrity
[152]. Therefore, these ﬁndings linked nuclear p-Akt to DSB repair and
cell survival. However, it not clear yet the protein kinase which could
phosphorylate Akt at the DSB foci, as ATM is not capable of directly
phosphorylating Akt [153].
5.4. RNA export
Many classes of RNA are exported from the nucleus, including
tRNA, rRNA, snRNA, and mRNA. A key player in mRNA nuclear export
is the protein referred to as REF/Aly, which is recruited to mRNA
during splicing [154]. Microinjection of antibodies to Aly blocked
mRNA export without affecting other transport mechanisms [155].
Aly localized to nuclear speckles where it interacted with PIP3
[156]. Nuclear Akt phosphorylated Aly on Thr 219 and this phosphor-
ylation was necessary for Aly binding to PIP3. Depletion of Aly by
siRNA resulted in reduced cell proliferation and mRNA export, and
these two processes required both Aly phosphorylation by Akt and
Aly interaction with PIP3 [156]. Thus, Aly phosphorylation could be
yet another mechanism by which nuclear Akt controls cell progression,
most likely by facilitating the export of mRNAs coding for proteins that
are involved in cell cycle regulation.
5.5. Cell differentiation
Akt signaling plays a major role in insulin-dependent adipogenic
differentiation [157]. An innovative strategy has been recently devel-
oped for the evaluation of the signaling roles played by Akt localized
at different subcellular locations during adipogenic differentiation.Selective Akt inhibitor peptides were generated using variations
of the Akt substrate recognition sequence (R-X-R-X-X-S/T) which
contained alanines in place of the target serines or threonines, cloned
in-frame with the cDNA encoding GST. A myc epitope tag was also
included, for facilitating peptide immunodetection [158]. Moreover,
the inhibitory peptides were engineered in-frame with peptides
directing to speciﬁc subcellular locations. Thus, for obtaining a selec-
tive inhibitor of nuclear Akt, the SV40 large T antigen amino acids
126–132 were used. Selective inhibition of nuclear Akt, affected the
localization and the transcriptional activity of FOXO3a in 3T3L1
preadipocytes induced to differentiate into adipocytes through stim-
ulation with insulin and dexamethasone. This resulted in a block of
adipogenic differentiation, as documented by analysis of Oil Red O
accumulation [158].
Stem cell therapies have been considered as novel strategies for
treating heart disorders [159]. However, only relatively modest
improvements in cardiac function and structure have been reported
so far, at least in part due to insufﬁcient stem cell proliferation and
viability after delivery [160]. To improve the outcome of stem cell
therapy, it is of critical importance to unravel mechanisms promoting
survival and proliferation of transplanted stem cells without inhibiting
lineage commitment. Pim-1 is a pro-survival and -proliferation kinase,
located down-stream of Akt, which was capable of enhancing myocar-
dial regeneration after infarction [161]. However, targeting of Akt to
the nucleus using a cDNAwith three in-frame NLS sequences, inhibited
the commitment of murine cardiac progenitor cells, and increased their
proliferation rate most likely due to enhanced transcription of cell
cycle-related genes (cyclin D1, cell division cycle 2 or CDC2, checkpoint
kinase 1 or Chk1). Moreover, elevated levels of Ser 133 p-CREB were
detected in these genetically engineered cells [162]. These results
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cardiomyocytes (see above). However, infarcted hearts receiving
intramyocardial injection of nuclear Akt-overexpressing progenitor
cells did not display long-term functional and structural improvements
when compared with controls. Therefore, these ﬁndings demonstrated
that full lineage commitment of cardiac progenitor cells is essential to
the regenerative response in infarcted hearts and that over-expression
of nuclear Akt could not be considered as a strategy for improving the
outcome of stem cell transplantation in the treatment of myocardial
infarction [162].
5.6. Tumorigenesis
The presence of nuclear p-Akt has been reported in lung, breast,
prostate, and thyroid cancers, as well as in AML [163–168]. The roles
played by nuclear Akt in cancer have not been investigated in detail so
far, however, it would seem logical that, once in the nucleus, Akt
could be involved in the regulation of signaling pathways involved in
neoplastic cell proliferation and survival. This theory is supported by
the ﬁnding that the promyelocytic leukemia protein (PML) tumor
suppressor is involved in dephosphorylating p-Akt inside the nucleus
[169]. PML resides in a special class of nuclear bodies, referred to as
PML bodies. PML bodies are involved in numerous functions that
include all kinds of protein modiﬁcations (acetylation/deacetylation,
ubiquitination/deubiquitination, phosphorylation/dephosphorylation,
SUMOylation, etc.) [170]. Even if PML is better known for the role it
plays in the pathogenesis of acute promyelocytic leukemia (a subset
of AML, see [171]), it has been demonstrated that PML expression is
reduced in prostate and colon cancer [172]. PML−/− murine embryo
ﬁbroblasts (MEFs) displayed a more evident nuclear Ser 473 p-Akt ac-
cumulation after serum stimulation than PML+/+ MEFs. Also, the
invasive prostate cancer cells of PML−/−mice showed a strong nuclear
localization of p-Akt. Accordingly, 80% of PML−/−MEFs had cytoplasmic
FOXO3a whereas 70% of wild-type cells still retained FOXO3a in the
nucleus [169]. Importantly, an Akt-insensitive FOXO3amutant retained
its nuclear localization in PML−/− MEFs. The reduction in nuclear
FOXO3a localization correlated with the inactivation of the transcrip-
tion of three genes that are under the control of the Akt-FOXO3a signal-
ing, i.e. pro-apoptotic Bim, the cell cycle inhibitor p27Kip1, and the DNA
repair protein, Gadd45 [169]. Considering that: A) okadaic acid (an
inhibitor of PP2A) did not affect the levels of nuclear Thr 308 p-Akt in
PML−/−MEFs, whereas it did in PML+/+MEFs; B) the A and C subunits
of PP2A interacted with PML and localized in PML bodies of PML+/+
MEF; and C) PP2A A and C subunits were excluded from the nucleus
of PML−/− MEFs, it was concluded that PML speciﬁcally recruited the
Thr 308 p-Akt phosphatase PP2A as well as p-Akt into PML nuclear
bodies [169]. Therefore, when PML levels were low, as in some kinds
of cancers, nuclear Akt phosphorylation and activity were high. More-
over, it was documented in a mouse model that PML loss markedly
accelerated intestinal tumor onset, incidence, and progression in
PTEN-heterozygous mutants that displayed only pre-cancerous polyps.
Furthermore, PTEN+/− PML−/− and PTEN+/− PML+/− males (but not
PTEN+/− mice that only displayed the in situ form of prostate cancer)
developed highly invasive cancers, suggesting that prostate epithelial
cells weremore sensitive to PML status than the intestine [169]. Impor-
tantly, staining for Ser 473 p-Akt was clearly increased in the nucleus in
polyps, normal colon, and in prostate lesions of PTEN+/− PML−/−mice
when compared with PTEN+/−mice. Therefore, even if most emphasis
is usually placed on PTEN deletion for explaining carcinogenesis in
prostate cancer [173], also PML could play an important role in the
control of p-Akt levels and tumor development.
In this context, it seems intriguing that long-term treatment with
high concentrations of statins of A549 lung cancer cells, resulted in a
decrease in nuclear Thr 308 p-Akt levels [174]. Thus, it has been
hypothesized that the cancer prevention effects of statins [175,176],
could be somehow related to down-regulation of nuclear p-Akt levels.It is very interesting that in the prostate, the extent of Akt nuclear
localization increased during the progression from normal tissue to
low grade prostatic intraepithelial neoplasia (PIN), high grade PIN,
and tumor [165]. Furthermore, in prostatic carcinomas the extent of
Akt nuclear localization correlated with the Gleason score, which is
the most powerful predictor of tumor progression after prostatecto-
my [177]. This observation suggested that nuclear Akt could be used
as an indicator of the prognosis of prostatic cancer. Higher levels
of nuclear p-Akt were also observed in invasive head and neck carci-
noma cell lines [178] as well as in glioblastomas [179]. Nevertheless,
in patients with estrogen receptor- and progesterone receptor-
expressing breast carcinomas, patients displaying positivity for nucle-
ar p-Akt had a longer survival than nuclear p-Akt-negative patients
[91].
6. Concluding remarks and future perspectives
It has been 15 years since Akt was demonstrated to migrate to the
nucleus. Although considerable progress has been made in under-
standing some of the roles nuclear Akt plays, yet there still are
many outstanding key issues that we do need to tackle. For example,
we do not know how exactly Akt enters the nucleus. Moreover, some
nuclear Akt substrates have been identiﬁed (p21Waf1/Cip1, p27Kip1, p300,
acinus, zyxin, etc.) and the functional consequences of their phosphor-
ylation by Akt have been understood. However, Akt phosphorylates
other nuclear substrates (lamin A for example, see [180]), but we do
not know how Akt-dependent phosphorylation could affect their
functions.
Moreover, it is emerging that nuclear Akt could interact with pro-
teins that are not Akt substrates (Ebp1, B23), yet these interactions
are of fundamental importance for regulating key processes taking
place within the nucleus. Progress has been recently made in the
identiﬁcation of several Akt-binding partners that modulate its acti-
vation, regulate its kinase activity, and deﬁne its impact on down-
stream biological responses in other cell districts [181]. Nuclear
Akt-interacting molecules, capable of context-dependent regulation
of Akt signaling, could have important roles in controlling signal
transduction pathways under both physiological and pathological
conditions. Therefore, the identiﬁcation of additional nuclear Akt-
interacting partners may provide a unique opportunity to better
understand the mechanisms that modulate Akt signaling activity in
the nucleus.
As stated above, Akt is involved in several different disorders.
Therefore, it is presently regarded as a potential target for the devel-
opment of innovative therapies. In some cases, such as cardiomyopa-
thies, it would see desirable to increase intra-nuclear Akt activity.
Thus, the possibility of selectively overexpressing Akt within the
nucleus appears particularly promising for the therapy of heart
disorders, as Akt is a powerful cardioprotective kinase with a well-
established capacity to prevent a variety of cardiomyopathic injuries
[182].
In case of anti-cancer therapies, the opposite is true, i.e. it could
very important to develop strategies to selectively block increased
nuclear Akt activity. Indeed, the selective inhibition of nuclear Akt
could avoid one of the most feared side effects of Akt activity down-
regulation through pharmacological inhibitors that is the blocking of
insulin-regulated glucose transport which results in hyperglycemia
and type 2 diabetes [183]. In this context, the data demonstrating
the possibility of synthesizing Akt inhibitors that could be selectively
targeted to the nucleus appear particularly intriguing [158]. Also the
possibility of targeting key interactions between Akt and its nuclear
partners, could provide yet another opportunity for modulating Akt
activity in the nucleus while sparing its functions in other cell
districts.
These lines of evidence lead us to believe that dissecting the com-
plexity of nuclear Akt signaling networks will be highly rewarding, as
2175A.M. Martelli et al. / Biochimica et Biophysica Acta 1823 (2012) 2168–2178it could undoubtedly offer valuable insight into the development of
novel therapeutic treatments for several disorders, including cancer.
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